JNJ logo

Johnson & Johnson (JNJ)

$282.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on JNJ

Market cap

$680.19B

EPS

6.58

P/E ratio

30.3

Price to sales

6.43

Dividend yield

1.897%

Beta

0.219933

Price on JNJ

Previous close

$285.75

Today's open

$288.99

Day's range

$282.33 - $290.25

52 week range

$195.90 - $290.25

Profile about JNJ

CEO

Joaquin Duato

Employees

140800

Headquarters

New Brunswick, NJ

Exchange

New York Stock Exchange

Shares outstanding

2.41B

Issue type

Common Stock

JNJ industries and sectors

Healthcare

Pharmaceuticals

News on JNJ

J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition

JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.

news source

Zacks Investment Research • 3 hours ago

news preview

J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts

J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.

news source

Zacks Investment Research • 3 hours ago

news preview

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

news source

Zacks Investment Research • 4 hours ago

news preview

Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

news source

Zacks Investment Research • 4 hours ago

news preview

Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & Johnson

DALLAS--(BUSINESS WIRE)--An appeals court in Louisiana has upheld a multimillion verdict against Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.In a Nov. 16 ruling, Louisiana's Fourth Circuit Court of Appeal affirmed a trial court's decision to increase damages awarded to the family of Jeannine Henderson. National plaintiffs trial firm Dean Omar Branham Shirley, LLP (DOBS) represented the Henderson family as well as.

news source

Business Wire • 2 hours ago

news preview

3 Bulletproof Passive Income Dividend Kings to Buy and Hold Forever

A pending IRS ruling, rising commodity costs, and more test whether the payouts of these passive income Dividend Kings can survive.

news source

24/7 Wall Street • 6 hours ago

news preview

Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.

news source

24/7 Wall Street • 5 hours ago

news preview

Johnson & Johnson vs. Pfizer: Consistency vs.

Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period. Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.

news source

The Motley Fool • an hour ago

news preview

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.

Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk. Johnson & Johnson maintained a consistent quarter-over-quarter upward trajectory, while Novo Nordisk reported mostly flat U.S. dollar figures with the exception of one isolated spike.

news source

The Motley Fool • 8 hours ago

news preview

Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

news source

WSJ • Nov 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Johnson & Johnson

Open an M1 investment account to buy and sell Johnson & Johnson commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in JNJ on M1